AXL and cancer: In many other cancer types, AXL signaling is a common resistance mechanism to targeted therapies, including ERK/MEK inhibitors (132–134), BRAF inhibitors (133–135), imatinib (136), sunitinib (137), WEE1 inhibitors (138), or lapatinib (139).